Adapting the drivers to the road: A new strategy for cancer evolution?

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 827-829

  Touat, M ^a,b   Dhermain, F ^c   Andre F ^b,c   Sanson, M ^d,e  

^a Drug Development Department (DITEP)   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

CANCER GENETICS; CANCER GROWTH; CPG ISLAND; EDITORIAL; EVOLUTION; GENE FREQUENCY; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GLIOMA; HUMAN; IDH1 GENE; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; GENETIC HETEROGENEITY; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; MOLECULAR EVOLUTION; PHENOTYPE;

CARCINOMA, RENAL CELL; EVOLUTION, MOLECULAR; GENETIC HETEROGENEITY; HUMANS; KIDNEY NEOPLASMS; PHENOTYPE;

EID: 84929084427     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv137     Document Type: Editorial

References (30)

1. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
2. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 2014; 15: 453.
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345.
4. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
5. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
6. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
7. Brennan CW, Verhaak RG, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155: 462-477.
8. de Bruin EC, McGranahan N, Mitter R et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251-256.
9. Anderson K, Lutz C, van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
10. Sottoriva A, Spiteri I, Piccirillo SG et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.
11. Johnson BE, Mazor T, Hong C et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014; 343: 189-193.
12. Snuderl M, Fazlollahi L, Le LP et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-817.
13. Patel AP, Tirosh I, Trombetta JJ et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344: 1396-1401.
14. Francis JM, Zhang CZ, Maire CL et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 2014; 4: 956-971.
15. Lass U, Nümann A, von Eckardstein K et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One 2012; 7: e41298.
16. Kim H, Zheng S, Amini SS et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 2015; 25: 316-327.
17. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
18. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
19. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
20. Walker EJ, Zhang C, Castelo-Branco P et al. Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res 2012; 72: 636-644.
21. Sasaki M, Knobbe CB, Munger JC et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659.
22. Wakimoto H, Tanaka S, Curry WT et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 2014; 20: 2898-2909.
23. Di Stefano AL, Fucci A, Frattini V et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin Cancer Res 2015 Jan 21 [epub ahead of print].
24. Cairncross JG, Wang M, Jenkins RB et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32: 783-790.
25. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15: 1164-1168.
26. Curtit E, Nerich V, Mansi L et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 2013; 18: 667-674.
27. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115.
28. Sanborn J, Salama S, Grifford M et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res 2013; 73: 6036-6045.
29. Jin G, Reitman ZJ, Duncan CG et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 2013; 73: 496-501.
30. Andre F, Mardis E, Salm M et al. Prioritizing targets for precision cancer medicine. Ann Oncol 2014; 25: 2295-2303.